

🔇 Tel: 400-999-8863 💌 Email:Upingbio.163.com



# Cleaved-Factor VII LC (R212) Polyclonal Antibody

can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to		
Reactivity Human;Rat;Mouse;   Applications WB;IHC;IF;ELISA   Gene Name F7   Protein Name Coagulation factor VII   Immunogen The antiserum was produced against synthesized peptide derived from human FA7. AA range:171-220   Specificity Cleaved-Factor VII LC (R212) Polycional Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.   Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.   Source Polycional, Rabbit,IgG   Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.   Dilution WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200   Concentration 1 mg/ml   Purity ≥90%   Storage Stability -20°C/1 year   Synonyms F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa   Observed Band 17kD   Cell Pathway Secreted.   Tissue Specificity Plasma.   Function catalytic activity:Selective cleavage of Arg-J-lie bond in factor X to form factor Xa, disease:Defects in F7 are the cause of factor VII deficiency jis area hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of infracerbard hemorrhages or hemarthroses, or, in contrast, moderaty hemorrhagic disease. The	Catalog No	YP-Ab-03348
Applications   WB;IHC;IF;ELISA     Gene Name   F7     Protein Name   Coagulation factor VII     Immunogen   The antiserum was produced against synthesized peptide derived from human FA7. AA range:171-220     Specificity   Cleaved-Factor VII LC (R212) Polyclonal Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.     Formulation   Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.     Source   Polyclonal, Rabbit,IgG     Purification   The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.     Dilution   WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/2000IF 1:50-200     Concentration   1 mg/ml     Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity:Selective cleavage of Arg-I-Ile bord in factor X to form factor X a, disease:Defects in F7 are the cause of factor VII is converted to factor VII is con	Isotype	IgG
Gene Name   F7     Protein Name   Coagulation factor VII     Immunogen   The antiserum was produced against synthesized peptide derived from human FA7. AA range:171-220     Specificity   Cleaved-Factor VII LC (R212) Polyclonal Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.     Formulation   Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.     Source   Polyclonal, Rabbit,IgG     Purification   The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.     Dilution   WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000. IF 1:50-200     Concentration   1 mg/ml     Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity:Selective cleavage of Arg-I-Ile bond in factor X to form factor X a, disease:Defects in F7 are the cause of factor VII deficiency JMM:227500].     Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the earaly occurrence of intracereval hemorrhages o	Reactivity	Human;Rat;Mouse;
Protein Name     Coagulation factor VII       Immunogen     The antiserum was produced against synthesized peptide derived from human FA7. AA range:171-220       Specificity     Cleaved-Factor VII LC (R212) Polyclonal Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.       Formulation     Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.       Source     Polyclonal, Rabbit,IgG       Purification     The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.       Dilution     WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000. IF 1:50-200       Concentration     1 mg/ml       Purity     ≥90%       Storage Stability     -20°C/1 year       Synonyms     F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa       Observed Band     17kD       Cell Pathway     Secreted.       Function     Catalytic activity:Selective cleavage of Arg-I-Ile bond in factor X to form factor Xa, disease:Defects in F7 are the cause of factor VII deficiency IMIM:227500]. Xa, disease:Defects in F7 are the cause of factor VII deficiency IMIM:227500]. Factor VII deficiency is a rare herediary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of indecice very low F7 level, function.Initiates the extrinsic pathway of blo	Applications	WB;IHC;IF;ELISA
Immunogen     The antiserum was produced against synthesized peptide derived from human FA7. AA range:171-220       Specificity     Cleaved-Factor VII LC (R212) Polyclonal Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.       Formulation     Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.       Source     Polyclonal, Rabbit,IgG       Purification     The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.       Dilution     WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200       Concentration     1 mg/ml       Purity     ≥90%       Storage Stability     -20°C/1 year       Synonyms     F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa       Observed Band     17kD       Cell Pathway     Secreted.       Function     catalytic activity:Selective cleavage of Arg-J-le bond in factor X to form factor Xa, disease:Defects in F7 are the cause of factor VII deficiency [MIM.227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intercerbaral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-huncosal hemorrhages epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptionatic despite a very	Gene Name	F7
FA7. AA range:171-220     Specificity   Cleaved-Factor VII LC (R212) Polyclonal Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.     Formulation   Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.     Source   Polyclonal, Rabbit,IgG     Purification   The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.     Dilution   WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200     Concentration   1 mg/ml     Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Function   catalytic activity:Selective cleavage of Arg-I-IIe bond in factor X to form factor Xa, disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500], Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture cab very severe, with the early occurrence of intraccerbal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucasi hemorrhages (epistaxis, menorhagic disease intervention. Numerous subjects are completely asymptomatic despite a very low F7 level, function. Initiates the extinsic pathway of blood coagulation. Serine proteeds that circulates in the ebiod in a zymogen form. Factor VII is converted to factor V	Protein Name	Coagulation factor VII
FormulationLiquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.SourcePolyclonal, Rabbit, IgGPurificationThe antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.DilutionWB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200Concentration1 mg/mlPurity≥90%Storage Stability-20°C/1 yearSynonymsF7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfaObserved Band17kDCell PathwaySecreted.Functioncatalytic activity:Selective cleavage of Arg-I-Ile bond in factor X to form factor Xa., disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of infracerebrah hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level, function. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII a fictor Xa, factor XIIa, factor VIIa, or thrombin by minor proteolysis. If the presence of tissue factor and caclour in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor VIIa, or thrombin by minor proteolysis. The vert actor vIIa the corver factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor VIIa, or thrombin by minor proteolysis.	Immunogen	FA7. AA range:171-220
Source     Polyclonal, Rabbit,IgG       Purification     The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.       Dilution     WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200       Concentration     1 mg/ml       Purity     ≥90%       Storage Stability     -20°C/1 year       Synonyms     F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa       Observed Band     17kD       Cell Pathway     Secreted.       Function     catalytic activity:Selective cleavage of Arg-I-Ile bond in factor X to form factor Xa, disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal intervention. Numerous subjects are completely asymptomatic despite a very low F7 level, function. Numerous subjects are completely asymptomatic despite a very low F7 level, functor tribitates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII a factor XIa, factor XIIa, factor XIa, a factor VII a factor VII is converted to factor VII a the presence of tissue factor and cacloum ions, factor VII is converted to factor VII a the origen a very low F7	Specificity	Cleaved-Factor VII LC (R212) Polyclonal Antibody detects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212.
Purification   The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.     Dilution   WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200     Concentration   1 mg/ml     Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity:Selective cleavage of Arg-J-lle bond in factor X to form factor Xa, disease: Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or heenorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7     Vertex   every severe, with the early occurrence of intracerebral hemorrhages or hemarthroses in the blood in a zymogen form. Factor VII is converted to factor VII and then converts factor X	Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
affinity-chromatography using epitope-specific immunogen.     Dilution   WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200     Concentration   1 mg/ml     Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity: Selective cleavage of Arg-I-IIe bond in factor X to form factor Xa, disease: Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses or hemarthroses or hemorrhages or book cogulation. Serine prot	Source	Polyclonal, Rabbit,IgG
Concentration   1 mg/ml     Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity:Selective cleavage of Arg-I-Ile bond in factor X to form factor Xa., disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level., function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII a by factor Xa, factor XIIa, factor XIIa, factor VIIa then converts factor X	Purification	
Purity   ≥90%     Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity:Selective cleavage of Arg-I-Ile bond in factor X to form factor Xa., disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of infracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level., function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII a by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VII a then converts factor X	Dilution	WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/20000 IF 1:50-200
Storage Stability   -20°C/1 year     Synonyms   F7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfa     Observed Band   17kD     Cell Pathway   Secreted.     Tissue Specificity   Plasma.     Function   catalytic activity:Selective cleavage of Arg-I-lle bond in factor X to form factor Xa., disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast moderate with cutaneous-mucosal hemorrhages or hemarthroses, or, in contrast is the blood in a zymogen form. Factor VII is converted to factor VII a by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. If the presence of tissue factor and calcium ions, factor VII a then converts factor X	Concentration	1 mg/ml
SynonymsF7; Coagulation factor VII; Proconvertin; Serum prothrombin conversion accelerator; SPCA; Eptacog alfaObserved Band17kDCell PathwaySecreted.Tissue SpecificityPlasma.Functioncatalytic activity:Selective cleavage of Arg-J-Ile bond in factor X to form factor Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor VIIa, then converts factor X is converted to factor VIIa then converts factor X	Purity	≥90%
accelerator; SPCA; Eptacog alfaObserved Band17kDCell PathwaySecreted.Tissue SpecificityPlasma.Functioncatalytic activity:Selective cleavage of Arg-]-Ile bond in factor X to form factor Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages or hemarthroses are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII a by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X	Storage Stability	-20°C/1 year
Cell PathwaySecreted.Tissue SpecificityPlasma.Functioncatalytic activity:Selective cleavage of Arg-]-Ile bond in factor X to form factor Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII a by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X	Synonyms	•
Tissue SpecificityPlasma.Functioncatalytic activity:Selective cleavage of Arg- -Ile bond in factor X to form factor Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X	Observed Band	17kD
<b>Function</b> catalytic activity:Selective cleavage of Arg- -Ile bond in factor X to form factor Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VII by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X	Cell Pathway	Secreted.
Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. Ir the presence of tissue factor and calcium ions, factor VIIa then converts factor X	Tissue Specificity	Plasma.
	Function	Xa.,disease:Defects in F7 are the cause of factor VII deficiency [MIM:227500]. Factor VII deficiency is a rare hereditary hemorrhagic disease. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Numerous subjects are completely asymptomatic despite a very low F7 level.,function:Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X



#### UpingBio technology Co.,Ltd

🔇 Tel: 400-999-8863 📼 Emall:Upingbio.163.com

Background	This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Ø Website: www.upingBio.com




#### UpingBio technology Co.,Ltd

😮 Tel: 400-999-8863 📼 Email:Upingbio.163.com


## Website: www.upingBio.com

### **Products Images**



Western Blot analysis of various cells using Cleaved-Factor VII LC (R212) Polyclonal Antibody

Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using FA7 (light chain,Cleaved-Arg212) Antibody. The picture on the right is blocked with the synthesized peptide.



Western blot analysis of lysates from Jurkat cells, treated with eto 25uM 24h, using FA7 (light chain,Cleaved-Arg212) Antibody. The lane on the right is blocked with the synthesized peptide.